ASH

ASH 2024: GLP-1s linked to reduced VTE risk in patients with diabetes

December 10, 2024

Study design: This retrospective, propensity score-matched multicenter database analysis used the TriNetX Analytics Network, encompassing over 250 million patients globally. Researchers compared the incidence of venous thromboembolism (VTE) in patients with T2DM treated with GLP-1 RAs vs. those treated with DPP-4 inhibitors. The study included 656,588 eligible patients, with 366,369 receiving GLP-1 RAs and 290,219 receiving DPP-4 inhibitors. Patients were matched 1:1 based on clinical variables, and subgroup analysis was performed based on obesity status.

Results: VTE incidence was 11.0 events per 1,000 patient-years in the GLP-1 RA cohort vs. 12.9 in the DPP-4 inhibitor cohort, translating to an 18% lower risk of VTE (HR, 0.82). According to subgroup analysis, GLP-1 RA use was associated with lower risks of pulmonary embolism (HR, 0.78) and deep venous thrombosis (HR, 0.85). These findings were consistent across both obese and non-obese subgroups.

Impact on clinical practice: The findings suggest that GLP-1 RAs not only aid in glycemic control but also reduce VTE risk in patients with T2DM, irrespective of obesity status, highlighting the medication’s potential dual benefit in clinical practice.

Source:

Chiang, CH, et al. (2024, December 8). Glucagon-like Peptide 1 Receptor Agonists Reduce the Risk of Venous Thromboembolism in Patients with Diabetes Irrespective of Obesity: A Propensity Score-Matched Multicenter Database Analysis. Abstract #701. Presented at American Society of Hematology Annual Meeting & Exposition. https://ash.confex.com/ash/2024/webprogram/Paper206409.html